322 related articles for article (PubMed ID: 12734333)
1. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.
Nowak AK; Lake RA; Marzo AL; Scott B; Heath WR; Collins EJ; Frelinger JA; Robinson BW
J Immunol; 2003 May; 170(10):4905-13. PubMed ID: 12734333
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.
Marzo AL; Kinnear BF; Lake RA; Frelinger JJ; Collins EJ; Robinson BW; Scott B
J Immunol; 2000 Dec; 165(11):6047-55. PubMed ID: 11086036
[TBL] [Abstract][Full Text] [Related]
3. Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo.
Redmond WL; Marincek BC; Sherman LA
J Immunol; 2005 Feb; 174(4):2046-53. PubMed ID: 15699134
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo.
Jackaman C; Majewski D; Fox SA; Nowak AK; Nelson DJ
Cancer Immunol Immunother; 2012 Dec; 61(12):2343-56. PubMed ID: 22714286
[TBL] [Abstract][Full Text] [Related]
5. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.
McDonnell AM; Lesterhuis WJ; Khong A; Nowak AK; Lake RA; Currie AJ; Robinson BW
Eur J Immunol; 2015 Jan; 45(1):49-59. PubMed ID: 25316312
[TBL] [Abstract][Full Text] [Related]
7. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice.
Lyman MA; Nugent CT; Marquardt KL; Biggs JA; Pamer EG; Sherman LA
J Immunol; 2005 Mar; 174(5):2563-72. PubMed ID: 15728462
[TBL] [Abstract][Full Text] [Related]
8. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
9. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
[TBL] [Abstract][Full Text] [Related]
10. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
[TBL] [Abstract][Full Text] [Related]
11. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen.
Ohlén C; Kalos M; Hong DJ; Shur AC; Greenberg PD
J Immunol; 2001 Feb; 166(4):2863-70. PubMed ID: 11160355
[TBL] [Abstract][Full Text] [Related]
12. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation.
Stumbles PA; Himbeck R; Frelinger JA; Collins EJ; Lake RA; Robinson BW
J Immunol; 2004 Nov; 173(10):5923-8. PubMed ID: 15528325
[TBL] [Abstract][Full Text] [Related]
13. Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.
Watson AM; Mylin LM; Thompson MM; Schell TD
J Immunol; 2012 Dec; 189(12):5549-60. PubMed ID: 23175697
[TBL] [Abstract][Full Text] [Related]
14. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens.
Morgan DJ; Kreuwel HT; Sherman LA
J Immunol; 1999 Jul; 163(2):723-7. PubMed ID: 10395663
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the Fas ligand/Fas-dependent apoptosis of antiretroviral, class I MHC tetramer-defined, CD8+ CTL by in vivo retrovirus-infected cells.
Rich RF; Green WR
J Immunol; 2002 Mar; 168(6):2751-8. PubMed ID: 11884442
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines.
Ronchetti A; Rovere P; Iezzi G; Galati G; Heltai S; Protti MP; Garancini MP; Manfredi AA; Rugarli C; Bellone M
J Immunol; 1999 Jul; 163(1):130-6. PubMed ID: 10384108
[TBL] [Abstract][Full Text] [Related]
17. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
18. Deletion of naive CD8 T cells requires persistent antigen and is not programmed by an initial signal from the tolerogenic APC.
Redmond WL; Hernandez J; Sherman LA
J Immunol; 2003 Dec; 171(12):6349-54. PubMed ID: 14662832
[TBL] [Abstract][Full Text] [Related]
19. Constitutive expression of Bcl-xL or Bcl-2 prevents peptide antigen-induced T cell deletion but does not influence T cell homeostasis after a viral infection.
Petschner F; Zimmerman C; Strasser A; Grillot D; Nunez G; Pircher H
Eur J Immunol; 1998 Feb; 28(2):560-9. PubMed ID: 9521066
[TBL] [Abstract][Full Text] [Related]
20. Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function.
Dumortier H; van Mierlo GJ; Egan D; van Ewijk W; Toes RE; Offringa R; Melief CJ
J Immunol; 2005 Jul; 175(2):855-63. PubMed ID: 16002683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
